Adnexal Diseases, Carcinoma, Endocrine Gland Neoplasm, Endocrine System Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasm, Female, Gonadal Disorders, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasm, Urogenital Neoplasms
Conditions
Keywords
Dietary supplements, Ocoxin-Viusid, Nutritional supplement, Ovarian Cancer, Metastasis
Brief summary
Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.
Detailed description
General Objectives -To identify the efficacy of the nutritional supplement Ocoxin-viusid to increase the quality of life of patients with epithelial advanced or metastatic ovarian cancer. Specific Objectives - Identify the influence of the research product on the nutritional status and quality of life of patients. - Describe the toxicity of the research product. - Identify the adverse reactions to the chemotherapy scheme and quantify the interruptions to it by acute toxicity. Quality of life. It will be measured as: - EORTC Questionnaire QLQ-C30 (Score of each item and general score). Measurement time: at the beginning and 3 weeks after the 3rd cycle of QT - EORTC Questionnaire QLQ-OV28 (Score of each item and general score). Measurement time: at the beginning and 3 weeks after the 3rd cycle of QT - Karnofsky index (Score of 0-100 points at intervals of 10). Measurement time: at the beginning, in each cycle of QT and 3 weeks after the 3rd cycle of QT
Interventions
DIETARY_SUPPLEMENTOcoxin-Viusid
Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
Sponsors
Catalysis SL
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female patients 18 years of age or older. 2. Patients with diagnosis of ovarian epithelial cancer in stages III (not resectable) and IV. 3. Patients with general health status according to the Karnofsky Index ≥ 70 (Annex 12). 4. Life expectancy equal to or greater than 3 months. 5. Patients who give their informed consent in writing to participate in the study. 6. Normal functioning of organs and bone marrow defined by the following parameters: -Hemoglobin ≥ 90 g / L - Total Leukocyte count ≥ 3.0 x 109 / L Absolute Neutrophil Count = 1.5 x 109 / L -Platelet count ≥ 100 x 109 / L -Glycemia values ≤ 10 Umol / L -Values of Creatinine and total bilirubin within the normal limits of the institution. -Values of AST / ALT ≤2.5 times the upper limit of the normal interval established in the institution. 7. Patients with a history of cardiovascular disease, with ejection fraction ≥ 55%, measured by echocardiogram.
Exclusion criteria
1. Patients who are receiving another research product. 2. Patients with known hypersensitivity to QT with Carboplatin, Cisplatin and / or Paclitaxel. 3. Patients in stage III tributary of surgical treatment at diagnosis. 4. Patients with known hypersensitivity to any ingredient of the product research. 5. Decompensated intercurrent diseases, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver diseases and psychiatric illnesses that could limit adherence to the requirements of the clinical trial or any other special condition that at the discretion of the physician put your health or life at risk during your participation in the trial. 6. Pregnancy, breastfeeding or puerperium. 7. Patients with brain metastases and/or leptomeningeal carcinosis. 8. Patients' carrier of the human immunodeficiency virus (HIV).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life | 4 months | It will measured by: - EORTC QLQ-C30 (Points of every item and final points) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nutritional State | 4 months | Body mass index |
Countries
Cuba
Outcome results
None listed